Pfizer Inc (PFE)
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at Pfizer Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Trading Day
Key levels of the most recently completed trading day — not a live quote.
52-Week Range
Current price 25.00 $ — 32% of the range above the low.
Lowest and highest closing price over the last 52 weeks. The marker shows where the current price sits within that range: close to the high speaks for strength, close to the low for weakness.
Basics
Performance
Technical Indicators
Calculated from the price history · as of 08/03/2026
Valuation
Profitability
Balance Sheet & Safety
Growth
Dividend
Quality & Screener
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Highlighted are things our editorial team noticed: green = stands out as strong, red = deserves a closer look. No single metric is a verdict on its own — always read it in context.
Analysts & Price Target
The price target sits 15.0% above the current price.
- Consensus
- Sell
- Analyst Ratings
- 25
Combined picture of the price targets and recommendations of every analyst covering the stock. Price targets are expectations for the next 12 months, not promises — and they often follow the price rather than predict it.
Estimates by Fiscal Year
| Fiscal Year | EPS Estimate ($) | EPS Range ($) | Revenue Estimate ($M) | Expected Growth | Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 2.95 | 2.80 – 3.12 | 61,743 | -8.5% | 24 |
| 12/31/2027 | 2.83 | 2.43 – 3.10 | 59,367 | -4.1% | 23 |
Average of the analyst estimates for the coming fiscal years. The range shows how far the most optimistic and the most cautious estimate sit apart — the wider it is, the less certain the expectation.
Next Reporting Date
- Expected Earnings per Share
- 0.68 $
Expected date of the next quarterly or annual figures. Dates do shift occasionally — only the invitation issued by the company is binding.
Revenue & Profit
Cash Flow
Balance Sheet
Margins
Per Share
Click the chart or tab into it, then use ← and → to step through the periods.
None of the selected stocks reports this metric. Pick another metric or switch between annual and quarterly.
· Total · per year
These companies report in different currencies — switch on “Indexed” or pick a margin for a fair comparison.
The figures could not be loaded right now.
Source: fundamental data
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | 0.07 | – | 17,763 | 21.90 | 2.30 | 6,721 | 5,804 |
| 2025: Q1 | 0.52 | -5.10 | 13,715 | -7.80 | 21.60 | 2,335 | 1,771 |
| 2025: Q2 | 0.51 | 12,003.80 | 14,653 | 10.30 | 19.90 | -582 | -1,200 |
| 2025: Q3 | 0.62 | -21.00 | 16,654 | -5.90 | 21.30 | 4,603 | 4,001 |
| 2025: Q4 | -0.29 | -510.20 | 17,557 | -1.20 | -9.40 | 5,349 | 4,504 |
| 2026: Q1 | 0.47 | -9.70 | 14,451 | 5.40 | 18.60 | 2,615 | 2,179 |
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
Annual Figures
| Fiscal Year | Revenue ($M) | EBIT ($M) | Net Income ($M) | EPS ($) | Operating Cash Flow ($M) | Equity ($M) | Total Assets ($M) |
|---|---|---|---|---|---|---|---|
| 2016 | 52,824 | 14,274 | 7,215 | 5.86 | 15,901 | 59,840 | 171,615 |
| 2017 | 52,546 | 14,391 | 21,305 | 17.58 | 16,470 | 71,656 | 171,797 |
| 2018 | 53,647 | 15,289 | 11,153 | 1.87 | 15,827 | 63,758 | 159,422 |
| 2019 | 41,172 | 7,511 | 16,273 | 2.87 | 12,588 | 63,446 | 167,488 |
| 2020 | 41,651 | 9,085 | 9,159 | 1.63 | 14,403 | 63,473 | 154,229 |
| 2021 | 81,288 | 20,793 | 22,147 | 3.88 | 32,580 | 77,463 | 181,477 |
| 2022 | 100,330 | 37,549 | 31,365 | 5.47 | 29,267 | 95,917 | 197,206 |
| 2023 | 59,553 | 5,292 | 2,133 | 0.37 | 8,700 | 89,288 | 226,501 |
| 2024 | 63,627 | 16,483 | 8,020 | 1.41 | 12,744 | 88,203 | 213,396 |
| 2025 | 62,579 | 15,437 | 7,770 | 1.37 | 11,705 | 86,476 | 208,160 |
Fiscal years from the audited annual reports, oldest first. EBIT is the operating profit before interest and taxes; total assets are everything the company owns.
About the Company
Pfizer Inc. erforscht, entwickelt, fertigt, vermarktet, vertreibt und verkauft biopharmazeutische Produkte in den USA und international.
| Employees | 75,000 |
|---|---|
| Headquarters | New York, NY |
| Address | 66 Hudson Boulevard East, 10001-2192 New York, United States |
| Phone | 212 733 2323 |
| Website | pfizer.com |
| IPO Date | 22. Jun 1942 |
| ISIN | US7170811035 |
| Stock Split | 1054:1000 on 11/17/2020 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Albert Bourla D.V.M., Ph.D. | Chairman of the Board & CEO | 1962 |
| David M. Denton | Executive VP & CFO | 1965 |
| Chris Boshoff FMedSci, M.D., Ph.D. | Chief Scientific Officer and President of Research & Development | 1964 |
| Douglas M. Lankler | Executive VP & Chief Legal Officer | 1966 |
| Aamir Malik | Executive VP & Chief U.S. Commercial Officer | 1976 |
| Jennifer B. Damico | Senior VP, Controller & Principal Accounting Officer | 1969 |
| Dennis P. Hancock | Executive VP & Chief Information Officer | – |
| Francesca M. DeMartino | Chief Investor Relations Officer | – |
| Payal Sahni Becher | Chief People Experience Officer & Executive VP | 1975 |
| Michael S. Vincent M.D., Ph.D. | Senior VP and Chief Scientific Officer of Inflammation & Immunology | – |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.